<DOC>
	<DOCNO>NCT02738333</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy therapy ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) safety tolerability LDV/SOF FDC sofosbuvir ( SOF ) + ribavirin ( RBV ) participants chronic genotype 2 HCV ( hepatitis C virus ) infection .</brief_summary>
	<brief_title>Ledipasvir/Sofosbuvir Fixed-Dose Combination 12 Weeks Participants With Chronic Genotype 2 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Key Chronic genotype 2 HCVinfected male nonpregnant/nonlactating female Aged 20 year old Treatment naive treatment experience At least 20 subject ChildPughA compensate cirrhosis . In Cohort 2 , participant must ineligible intolerant RBV . Key Previous exposure NS5A NS5B inhibitor Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Pregnant nurse female male pregnant female partner Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>